Delving into the Latest Updates on Magnesium valproate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Magmesium Valproate, MagneVal

Target

GABA transaminase x GSK-3

Mechanism

GABA transaminase inhibitors(Gamma-amino-N-butyrate transaminase inhibitors), GSK-3 inhibitors(Glycogen synthase kinase-3 inhibitors)

Therapeutic Areas

Nervous System DiseasesNeoplasms

Active Indication

EpilepsySolid tumor

Inactive Indication

Bipolar Disorder

Originator Organization

Hunan Xiangzhong Pharmaceutical Co., Ltd.

Active Organization

Hunan Xiangzhong Pharmaceutical Co., Ltd.Instituto Nacional de Cancerología

Inactive Organization

BioLink Life Sciences, Inc.

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC16H32MgO4

InChIKeyAOKPYFGZNIEWKA-UHFFFAOYSA-N

CAS Registry62959-43-7

View All Structures (2)

This is a pilot study in 40 subjects with definite ALS to evaluate the efficacy of valproate and lithium carbonate. After a random assignation of the dual treatment vs. placebo, a follow-up of 20 months will allow to know the clinical and functional evolution so as the status of biomarkers under each treatment.

Start Date01 May 2016

Sponsor / Collaborator-

NCT00533299 / Unknown statusPhase 3IIT

Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer.

The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or gemcitabine, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus topotecan over placebo plus topotecan upon progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to topotecan will increase progression-free survival from 6 to 9 months as compared with the same regimen of chemotherapy plus placebo.

Start Date01 Aug 2007

Sponsor / Collaborator-

NCT00532818 / Unknown statusPhase 3IIT

Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer.

The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved. Epigenetic aberrations play an important role in cancer progression by silencing growth regulatory genes and there is now evidence that inhibitors of DNA methylation and HDAC inhibition synergize the cytotoxicity of chemotherapy.
Objective. To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival.
Hypothesis. Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo.

Start Date01 Jul 2007

Sponsor / Collaborator

Psicofarma SA de CV

100 Clinical Results associated with Magnesium valproate

Login to view more data

100 Translational Medicine associated with Magnesium valproate

Login to view more data

100 Patents (Medical) associated with Magnesium valproate

Login to view more data

53

Literatures (Medical) associated with Magnesium valproate

01 Sep 2023·European Journal of Pharmacology

Corrigendum to “Cardioprotective effects of magnesium valproate in type 2 diabetes mellitus” [Eur. J. Pharmacol. 728 (5 April 2014) 128–134]

Author: Porwal, Urvashi ; Patel, Bhoomika M ; Raghunathan, Suchi

01 Apr 2023·Alternative therapies in health and medicine

Systematic Review and Meta-Analysis of Salt Valproate Preventing Switch Associated with Antidepressants in Chinese Patients With Depressive Episodes.

Review

Author: Lv, Wangqiang ; Dong, Shen ; Fengli, Sun ; Weidong, Jin

ObjectiveThis overview of systematic reviews (SRs) and meta-analyses aims to critically appraise the methodology and reporting quality of relevant SRs and meta-analyses with the aim of identifying whether or not the use of valproate can prevent the switch to mania associated with antidepressant treatment in Chinese patients with depressive episodes.MethodsElectronic databases China National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP database) and Wanfang Database were searched for related SRs and meta-analyses from inception to the search date within Chinese restrictions. A total of 2 reviewers independently selected SRs and meta-analyses and collected related data, and a third reviewer was introduced if any disagreement occurred during the assessment. The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) and the US Agency for Healthcare Research and Quality (AHRQ) were employed to evaluate quality of the reporting and methodology.ResultsThe switch rate in the sodium valproate group by 99% and was significantly lower than in the antidepressant-only group (0% vs 5.7%; OR = 0.18; 95% CI, 0.04-0.84; Z = 2.18; P = .03). The magnesium valproate group was similar to the sodium valproate group in switch rate; the switch rate in the antidepressant group was (2.2% vs 16.92%; OR = 0.11; 95% CI, 0.03-0.39; Z = 3.47; P = .0005). The switch rate in the salt valproate combined with a selective serotonin reuptake inhibitor (SSRI) group was lower than in the SSRI group (0.51% vs 8.4%; OR = 0.15; 95% CI, 0.04-0.51; Z = 3.01; P = .003). The switch rate in the valproate combined with serotonin noradrenaline reuptake inhibitor (SNRI) group was similar to the valproate combined with SNRI group (2.3% vs 17.5%; OR = 0.12; 95% CI, 0.03-0.53; Z = 2.79; P = .05).ConclusionSalt valproate can reduce the switch rate related to antidepressant treatment in patients with depression.

01 Jan 2023·Frontiers in pharmacology

Case report: Progressive skin rash and lymphadenopathy associated with lamotrigine-valproic acid combination in a bipolar adolescent.

Author: Qiu, Fangxinrui ; Liu, Shiyu ; Duan, Yingxu ; Zhao, Die ; Zhou, Jingyuan ; Qiu, Changjian

Background: Lamotrigine may cause severe skin reactions. There is a known interaction between lamotrigine and valproic acid with an increase in lamotrigine levels and lamotrigine toxicity risk. Few cases of severe rash and systemic reactions in bipolar patients using lamotrigine and valproate have been reported. Here, we report a rare case of severe skin rash and lymphadenopathy associated with lamotrigine-valproic acid combination. Case presentation: An 18-year-old female adolescent with bipolar disorder type I was treated with lamotrigine, magnesium valproate, and perospirone for 12 days. After the last dose of lamotrigine, she abruptly developed generalized rash and swollen lymph nodes, which continued to progress over the next 3 days. This finally subsided after stopping valproate and with glucocorticoid treatment. Conclusion: This case suggests that lamotrigine-valproic acid combination may cause not only rash but also lymphadenopathy. Even though the aforementioned reactions appear after the last dose of lamotrigine, it cannot be ruled out as suspicious. We recommend caution during titration of lamotrigine and valproate and early withdrawal of both when signs of hypersensitivity appear.

100 Deals associated with Magnesium valproate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N03A	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Epilepsy	CN	Hunan Xiangzhong Pharmaceutical Co., Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 2	MX	Instituto Nacional de Cancerología	01 Sep 2007
Bipolar Disorder	Discovery	US	BioLink Life Sciences, Inc.	-
Epilepsy	Discovery	US	BioLink Life Sciences, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


IEC2013	Not Applicable	Second line	-	Magnesium Valproate	sehmpeeysa(nduzhyiarj) = supply, adherence and some drug interactions that in all cases they were responsible for therapeutic failure or adverse reactions to the initial medication kyklvhlwye (udnzglwyvk ) View more	Positive	24 Jun 2013